Latest Revenue Growth News

HighCom Limited reveals a challenging first half of FY26 with losses linked to the US Government shutdown but signals a confident turnaround in the second half driven by diversification and operational improvements.

AVITA Medical reported solid 11% revenue growth in 2025 and secured a $60 million credit facility to fuel its next phase of expansion, projecting up to 19% revenue growth in 2026.

RocketBoots Limited has slightly increased its recent capital raising, issuing an additional 100,000 shares to raise a total of A$7.025 million, reinforcing its push into international markets.

Eden Innovations has secured a $2.2 million strategic investment to fully repay its remaining iBorrow debt, eliminating costly interest payments and strengthening its balance sheet ahead of anticipated revenue growth.

ReNerve Limited has secured broader regulatory approval in Hong Kong for its NervAlign® Nerve Cuff, enabling access to both public and private hospitals and validating the device’s clinical benefits through independent review.

Super Retail Group has reported a record 13.1% sales growth in the first half of FY26, with normalised profit before tax expected between $172 million and $175 million despite margin challenges and weather impacts.

EBR Systems reported a doubling of WiSE System implants in Q4 FY2025 alongside the launch of key clinical studies and preliminary revenue guidance, signalling strong commercial and clinical momentum.

Mesoblast Limited reports a 60% jump in Ryoncil sales for the December quarter, underpinned by a new $125 million financing facility that strengthens its balance sheet and strategic flexibility.

FlexiRoam has secured a key partnership to provide AI-enhanced connectivity for Malaysia’s national welfare initiative, supporting over 8 million recipients and marking a strategic step into mission-critical government infrastructure.

CurveBeam AI has received official Chinese regulatory approval for a strategic $10 million investment from WEGO Orthopaedics, marking a major step in its expansion into Greater China. The initial $4 million tranche at a premium share price is expected imminently, underpinning a decade-long commercialisation deal.

Orthocell has reported a record $3.2 million in quarterly revenue, marking its seventh consecutive quarter of growth, driven by strong sales of its Remplir™ nerve repair product in Australia and early traction in the US market.

Carbonxt Group Limited has raised $600,000 through a share placement to fund working capital and increase its ownership in New Carbon Processing, LLC to 46.7%. The move supports progress at New Carbon’s Kentucky facility as it nears commissioning.